publication date: May. 1, 2014


NCI CTEP Approved Trials for the Month of April

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I

PBTC-042: Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors. Pediatric Brain Tumor Consortium; Gururangan, Sridharan. (919) 668-6288

Phase I/II

ADVL1312: A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors. COG Phase 1 Consortium; Cole, Kristina Ann. (267) 426-2285

ADVL1411: A Phase 1/2 Study of BMN 673 (IND# 121510), an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies. COG Phase 1 Consortium; Schafer, Eric Stephen. (832) 825-4241

URCC-13070: Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers. University of Rochester; Mohile, Supriya Gupta. (585) 275-9319

Phase II

9416: A Randomized Phase II Trial of Cisplatin with or Without Wee1 Kinase Inhibitor MK-1775 for First-Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN). University Health Network-Princess Margaret Hospital; Winquist, Eric William. 519-685-6840

Phase III

E2112: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer. ECOG-ACRIN Cancer Research Group; Connolly, Roisin M. (410) 614-9217

Other Phases

Continue reading TCCL April – CTEP Approved Trials

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.